新型药物SL-401通过靶向浆细胞样树突状细胞、破骨细胞生成和肿瘤干细胞样细胞诱导抗骨髓瘤活性
研究显示多发性骨髓瘤骨髓微环境中浆细胞样树突状细胞(pDC)增多,pDC与骨髓瘤细胞相互作用上调白介素-3(IL-3),后者促进pDC存活和骨髓瘤细胞生长。靶向IL-3受体的SL-401在体外和体内模型中降低pDC活力、阻断pDC诱导的骨髓瘤细胞生长、协同增强硼替佐米和泊马度胺的抗骨髓瘤活性,并抑制破骨细胞形成和骨吸收、降低表达IL-3受体的肿瘤干细胞样细胞活力,为临床试验提供临床前依据。
要点
- SL-401靶向IL-3受体,在骨髓瘤微环境中降低pDC活力并阻断pDC诱导的骨髓瘤细胞生长。
- SL-401协同增强硼替佐米和泊马度胺的抗骨髓瘤活性。
- SL-401抑制单核细胞来源破骨细胞形成和骨吸收,并降低IL-3受体表达肿瘤干细胞样细胞活力。
核心结论
- SL-401在骨髓瘤微环境的体外和体内模型中降低pDC活力、阻断pDC诱导的骨髓瘤细胞生长、协同增强硼替佐米和泊马度胺的抗骨髓瘤活性、抑制破骨细胞生成和骨吸收、降低IL-3受体表达肿瘤干细胞样细胞活力。
- 研究为SL-401的临床试验提供临床前依据,以阻断pDC诱导的骨髓瘤细胞生长、抑制破骨细胞生成并靶向骨髓瘤干细胞样细胞亚群。
研究设计与样本
- 研究采用多发性骨髓瘤骨髓微环境的体外和体内模型。
主要发现
- 多发性骨髓瘤骨髓微环境中肿瘤促进性、免疫抑制性和耐药性pDC数量增加。
- pDC与骨髓瘤细胞相互作用上调IL-3,IL-3刺激pDC存活和骨髓瘤细胞生长。
- SL-401在体外和体内模型中降低pDC活力、阻断pDC诱导的骨髓瘤细胞生长,并协同增强硼替佐米和泊马度胺的抗骨髓瘤活性。
- 破骨细胞祖细胞表达IL-3受体,SL-401消除单核细胞来源的破骨细胞形成和骨吸收。
- SL-401降低多发性骨髓瘤中表达IL-3受体的肿瘤干细胞样细胞活力。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel therapies for multiple myeloma (MM) can target mechanism(s) in the host-MM bone marrow (BM) microenvironment mediating MM progression and chemoresistance. Our studies showed increased numbers of tumor-promoting, immunosuppressive and drug-resistant plasmacytoid dendritic cells (pDCs) in the MM BM microenvironment. pDC-MM cell interactions upregulate interleukin-3 (IL-3), which stimulates both pDC survival and MM cell growth. Since IL-3 R is highly expressed on pDCs in the MM BM milieu, we here targeted pDCs using a novel IL-3 R-targeted therapeutic SL-401. In both in vitro and in vivo models of MM in its BM milieu, SL-401 decreases viability of pDCs, blocks pDC-induced MM cell growth, and synergistically enhances anti-MM activity of bortezomib and pomalidomide. Besides promoting pDC survival and MM cell growth, IL-3 also mediates progression of osteolytic bone disease in MM. Osteoclast (OCL) progenitor cells express IL-3 R, and we show that SL-401 abrogates monocyte-derived OCL formation and bone resorption. Finally, we show that SL-401 also decreases the viability of IL-3 R-expressing cancer stem-like cells in MM. Overall, our study provides the preclinical basis for clinical trials of SL-401 to block pDC-induced MM cell growth, inhibit osteoclastogenesis and target MM stem-like cell subpopulations to improve patient outcome in MM.
引用
- Ray A, Das DS, Song Y, et al. A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells. Leukemia. 2017. PMID: 28479592. doi:10.1038/leu.2017.135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。